Siemens Healthineers has become a licensed partner in the Bio-Hermes-002 Alzheimer’s study.
Erin Brady April 13, 2026
The Global Alzheimer’s Platform Foundation (GAP) has announced that Siemens Healthineers has joined the Bio-Hermes-002 study alongside several other industry leaders. Siemens is now a licensed partner of the study, aiming to enhance Alzheimer’s diagnostics.
Specifically, Siemens Healthineers will work to “change the paradigm of early-stage disease diagnostics and monitoring, building upon findings from Bio-Hermes-001.” The Bio-Hermes-002 study will analyze biomarker data stored on the secure AD Workbench to “assess, diagnose or predict” disease presence/risk. https://www.mlo-online.com/disease/news/55370392/siemens-healthineers-joins-bio-hermes-002-study-for-alzheimers-research